ArticleJournal of translational medicine2026
Single-cell transcriptomic analysis and machine learning identify ATAD3A as a key gene that stabilizes mitochondrial-endoplasmic reticulum membranes, promoting bladder cancer progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMitochondria-associated endoplasmic reticulum membranes (MAM) play a critical regulatory role in cancer, yet their function in bladder cancer (BCa) remains unclear.
methodsThis study conducted a comprehensive analysis of extensive RNA sequencing and single-cell transcriptomic data. A MAM risk feature model was constructed and evaluated using LASSO-Cox regression, Kaplan-Meier survival curves, and receiver operating characteristic (ROC) analysis. Cell communication networks were decoded using CellChat, and tumor-infiltrating immune cells were quantified through CIBERSORT. Machine learning, OncoPredict, Scissor algorithm, and spatial transcriptomics were employed to analyze chemical reactions. The tumor-promoting functions and molecular mechanisms of ATAD3A were validated through cell and animal models, as well as transmission electron microscopy and fluorescence confocal microscopy.
resultsThis study systematically delineates the gene expression profile of MAM in BCa and constructs a robust MAM prognostic signature that effectively predicts poor patient outcomes. A high MAM score is significantly associated with an immunosuppressive microenvironment and chemotherapy resistance. Using machine learning, we developed a random forest model that successfully identified ATAD3A as a key gene predicting cisplatin resistance, which is significantly correlated with platinum resistance at both single-cell and spatial transcriptomic levels. Further validation shows that ATAD3A is highly expressed in BCa tissue, and its knockdown significantly suppresses tumor growth. Mechanistically, ATAD3A maintains MAM structural integrity, regulates mitochondrial calcium homeostasis and membrane potential, thereby promoting cellular homeostasis and enhancing chemotherapy resistance.
conclusionThis study connects MAM to BCa chemotherapy resistance through machine learning and multi-omics analysis, establishing ATAD3A as a prognostic biomarker and potential therapeutic target in BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.